# Monoclonal Antibody Therapy in Treating Patients With Recurrent Non-Hodgkin's Lymphoma

> **NCT00004101** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 35 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **BIOLOGICAL:** apolizumab

## Key facts

- **NCT ID:** NCT00004101
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-11
- **Primary completion:** 2005-06
- **Final completion:** —
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2013-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00004101

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00004101, "Monoclonal Antibody Therapy in Treating Patients With Recurrent Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00004101. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*